APPW2025

Co-hosted by: NEXEL Co.,Ltd

Current preclinical drug development faces challenges in accurately predicting cardiac toxicity, particularly arrhythmia risk. To overcome the limitations inherent in 2D monolayer cultures, we developed and utilized hiPSC-derived COs, which provides a more physiologically relevant model of the human heart.hiPSC-CMs offer a promising alternative for the early detection of cardiac arrhythmia risks in drug development, while hiPSC-derived organoid models provide enhanced functionality and reliable disease modeling. By combining 2D hiPSC-CMs with organoid models, we could achieve a more comprehensive evaluation of investigational drugs.